
31 million tons of supercharged seaweed is creeping toward beaches in Florida and around the Caribbean
Floating in brown islands of algae, this year's sargassum bloom has already broken its own size record by millions of tons — and the growing season isn't done yet.
Now stretching across some 5,500 miles of ocean, the annual bloom is more than just an eyesore: Sargassum hurts ecosystems and economies wherever its overgrown arms reach. And they are spreading into Florida's waterways, coating marinas and beaches in the Miami area.
'Sargassum goes from being a very beneficial resource of the North Atlantic to becoming what we refer to as … a harmful algal bloom, when it comes ashore in excessive biomass,' said Brian LaPointe, a research professor at Florida Atlantic University's Harbor Branch Oceanographic Institute.
'What we have seen since 2011 are excessive inundation events all around the Caribbean region, the Gulf, as well as the South Florida region,' explained LaPointe, who has studied the seaweed for decades.
For more than a decade, Atlantic coastal communities have been inundated by more and more sargassum. Images of white sand beaches stretching into azure waters have been altered by the toxic and putrid invasion. In the water, it's home to larvae and other organisms that can irritate the skin of any passing swimmers.
As it rots on shore, it emits harmful gases— an infamous stench.
It's a blight on beaches that repels tourists during the high-travel season, ultimately hurting towns that rely on tourism to fuel their economy.
Rising ocean temperatures due to human-caused climate change have spurred this sargassum surplus, supercharging the seaweed. In April, the University of South Florida estimated this year's bloom is already at 31 million tons — '40% more' than the previous record from June 2022, according to LaPointe.
The sargassum bloom itself is not a new phenomenon. It's long provided a home to species from sea turtles to fish as winds and tides push it from the coast of West Africa toward Brazil, up into the Caribbean and the Gulf of Mexico.
'Sargassum has been around for eons. Colombus ran into it right in the Sargasso Sea,' La Pointe told CNN. 'But what we are seeing now is above and beyond what we had historically.'
Sargassum's growth is also being driven by an excess of nitrogen in the water, LaPointe said — and that's a key factor behind this year's monster bloom.
Some nitrogen may be coming from the atmosphere, carried in the air from the burning of fossil fuels or dust from the Sahara Desert.
But there's one major source: agricultural fertilizers. Used in the American heartland as well as in the Amazon basin where there's been rapid deforestation for farming, the nitrogen-rich fertilizers are likely making their way into the Mississippi and Amazon Rivers as runoff, which then carries it into the Atlantic.
And the Amazon basin has notched its lowest water levels on record amid two straight years of extreme drought — the worst since records began being kept in 1950.
'What happens when you have a severe drought in the world's largest watershed? You get all this organic matter that dries up. Plants dry up and die. And then, when the rain hits, what happens? All those nutrients wash out,' LaPointe hypothesized, adding that 'first flush' events like this are full of concentrations of nitrogen and phosphorus at peak levels, which go on to feed the bloom's growth explosion.
Toxic to tourism
Unsurprisingly, the constant inundation of stinky, brown seaweed along the coast is not good for economies driven by tourism.
This year's bloom has already been making an appearance along Florida's east coast, from the Keys to Saint Augustine, according to reports on a sargassum monitoring site, and southeastern Florida could see more in the coming weeks. The unwanted algae has also been spotted in popular destinations from Mexico to Barbados and farther south.
'It's not good for the environment, because what you're smelling is hydrogen sulfide gas which is toxic,' LaPointe said.
In some places, the beaches are cleared of seaweed from sunrise to sunset — an expensive endeavor combing up sargassum that inundates the coastline with every wave. Some of the machinery used to clean the beaches adds its own pollution to the scenic environment, too.
'Resorts have gone out to their beaches with heavy equipment like front-end loaders, bulldozers, dump trucks to try to remove the sargassum to make those beaches available,' LaPointe said, as tourists don't want mounds of sargassum to mar their tropical views. 'The tourists check out, and they don't come back.'
This is a major tangle for places like Mexico's Yucatán Peninsula, which exists in the heart of the sargassum belt between the Gulf of Mexico and the Caribbean Sea.
The problem has become so pronounced along the Riviera Maya, Mara Lezama, the governor of Quintana Roo, a state in the peninsula, has taken to social media to say her state is working with the Mexican Navy to collect the seaweed in the water while also installing a nearly 6-mile barrier in the water to protect Quintana Roo's Mahahual, Playa del Carmen and Puerto Morelos beaches.
The barriers, which are similar to booms that contain oil spills, are just over a yard deep and are designed to keep the seaweed from reaching the coast.
As it approaches, the decaying sargassum can also create health problems for animals and humans.
'When it arrives to the coastal area, it creates a shadow from the sun, so everything that is below — all the life is not getting sunlight. So, it starts to affect the ecosystem, coastal ecosystem, and many things die,' said Christian Appendini, professor at the Universidad Nacional Autónoma de México.
'Then when it gets over the beach, it starts to decompose. And when it decomposes, it releases all the contaminants it has.'
Ammonia is another problem emitted by the decaying seaweed, LaPointe noted. The chemical compound 'strips the oxygen out of the waters along our coastal ecosystems like mangroves, coral reefs, seagrass beds,' he said.
'When you see the mass inundation events along the beaches, say in the Mexican Riviera, for example, you don't see many fish or crabs,' LaPointe continued. 'If you do, they're probably dead because there's no oxygen in that water.'
Seaweed with a silver lining
With sargassum cementing itself as an ongoing problem, some are looking into putting the seaweed to good use, instead.
Appendini says research is ongoing to find ways to use the sargassum for biofuel, building bricks, or as membranes for cleaning water, since it is particularly absorbent.
'They absorb all the heavy metals and contaminants in the water,' he told CNN. 'That's also why sargassum can be very toxic, because when it's drifting in the ocean it's just assimilating all the toxic elements in the ocean like cadmium, arsenic and other minerals and elements.'
There's also the possibility of carbon sequestration by sinking the excessive biomass to the bottom of the ocean. And there's interest in possibly using sargassum to replace one of the globe's other problems: plastic.
'If we could harvest this sargassum and produce this biodegradable product that could replace single use plastics, that would begin to restore the oceans regarding the serious plastic pollution that we're seeing,' LaPointe said.
As the sargassum situation remains pervasive for more than a decade now, Appendini said the record-breaking bloom should make the world pay attention.
'I think the sargassum blooms are like a warning that we need to be more mindful of how we are developing in this world,' Appendini said. 'We need to change … how we do things.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


TechCrunch
2 hours ago
- TechCrunch
Starship launches could delay Florida flights up to 2 hours, FAA says
As regulators weigh SpaceX's plans to launch its massive Starship rocket from Kennedy Space Center, federal documents warn those flights could ripple through Florida airspace, forcing ground stops at multiple airports, reroutes, and delays of up to two hours. Even after launch, reentry of Starship's two stages could require ground stops at some of the busiest airports in the country, according to a draft environmental impact statement (EIS) released by the Federal Aviation Administration this month. Florida airports affected by the launches may include Orlando International, Miami International, Tampa International, and Fort Lauderdale/Hollywood International. Average delays could be as long as 40 minutes to 2 hours for launches and Super Heavy booster landings, and 40 minutes to one hour for Starship reentries. Diversions and cancellations are possible, the FAA said in a companion slide deck. To manage risk, the FAA would establish Aircraft Hazard Areas (AHAs) over potentially impacted zones, as it does for commercial space launches today. Depending on the Starship flight trajectory, those zones could overlay routes above the Atlantic, parts of the Gulf of Mexico, the Caribbean, and airspace in several Central American countries. 'AHAs may necessitate the closure of dozens of coastal and deep-water oceanic airways over the Atlantic Ocean, requiring substantial aircraft rerouting to avoid the AHAs,' the draft EIS says regarding Starship launches. Tampa International Airport spokesperson Emily Nipps told TechCrunch the airport has not been involved in any briefings or procedural planning with the FAA or SpaceX, so far. However, a day after TechCrunch sent its inquiries to the relevant airports and the FAA, Nipps said the airport was informed it would be having those discussions 'soon.' Techcrunch event Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital, Elad Gil — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $600+ before prices rise. Tech and VC heavyweights join the Disrupt 2025 agenda Netflix, ElevenLabs, Wayve, Sequoia Capital — just a few of the heavy hitters joining the Disrupt 2025 agenda. They're here to deliver the insights that fuel startup growth and sharpen your edge. Don't miss the 20th anniversary of TechCrunch Disrupt, and a chance to learn from the top voices in tech — grab your ticket now and save up to $675 before prices rise. San Francisco | REGISTER NOW 'Whether that changes anything for us operationally, I don't yet know,' she said. A spokesperson for Miami International said they have not received any briefings on possible ground stops. SpaceX has been launching its flagship Falcon rockets from the Florida coast for years, and that cadence has sharply increased since 2020. Despite launching over 80 Falcon rockets from the Eastern Range last year, these launches don't typically interrupt commercial airlines. But the Falcon rockets are substantially different from Starship: Falcon's smaller size means a smaller possible footprint for debris in the case of an anomaly, and the Falcon launches are at this point predictable and mature. Starship is in a much earlier stage of development, with vehicles still occasionally blowing up during both ground tests and orbital flights. Indeed, the draft EIS notes that the size of airspace closures may vary with each Starship mission, and that it could shrink as the vehicle becomes more reliable. An FAA spokesperson said the agency has already engaged with aviation organizations, and worked with SpaceX to develop notional launch and reentry trajectories. Prior to launch, the agency will also distribute a final Airspace Management Plan. The FAA relies on a number of factors, including the number of affected passengers, launch window duration, and major holidays when determining when a space launch can proceed, the spokesperson added. Starship is SpaceX's next-generation launch system designed for travel to the Moon and Mars. The 400-foot-tall rocket is composed of two stages: an upper stage, also called Starship, and a Super Heavy booster. Both stages are designed to be fully reusable and rapidly refurbished for high-cadence satellite delivery and missions to deep space. Today, SpaceX conducts all Starship launch activities from Starbase in south Texas. But the company is looking to expand operations to NASA's Kennedy Space Center, prompting the environmental review. That review is conducted by the FAA in cooperation with NASA, the Air Force, the Fish and Wildlife Service, and other federal agencies. The draft EIS analyzes up to 44 Starship launches per year, which could include up to 44 Super Heavy booster landings and 44 Starship landings. Super Heavy could land back at LC-39A, the launch pad at KSC, on a droneship, or be expended in the Atlantic. Starship landings could likewise occur at the pad, on a ship, or as water splashdowns with recovery in the Atlantic, Pacific, or Indian Oceans. The FAA said in the draft EIS that while temporary airspace closures may impact commercial airlines and other stakeholders, 'mitigation strategies such as pre-coordinated reroutes, dynamic scheduling, and time-based traffic flow management could reduce operational burdens.' Today, FAA uses a prototype tool called Space Data Integrator, which ingests real-time flight data from SpaceX and other operators to shrink the amount of time airspace is closed. The regulator says it wants to develop more tools to beef out its situational awareness capability, and each time Starship launches it will get more data on its operations. The U.S. Space Force is running a parallel environmental review at neighboring Cape Canaveral Space Force Base that analyzes up to 76 annual Starship launches. While the draft EIS for that site states Starship launches would result in airspace closures, it says details of the closures are not yet known because the site is expected to take months to prepare.
Yahoo
7 hours ago
- Yahoo
Human Microbiome Market worth $7.09 billion by 2031 with 31.0% CAGR
DELRAY BEACH, Fla., Aug. 20, 2025 /PRNewswire/ -- The global Human Microbiome Market, valued at US$0.91 billion in 2024, stood at US$1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$7.09 billion by the end of the period. The primary drivers behind the expansion of this industry are the technological advancement in microbiome sequencing, the collaborative efforts between the microbiome industry, organizations, and academia for microbiome research, and the increase in the number of startups and SMEs exploring the microbiome niche, and further opportunities such as the increase in demand for personalized medicine and the emergence of synbiotics may help drive the human microbiome market. Download PDF Brochure: Browse in-depth TOC on "Human Microbiome Market" 416 - Tables64 - Figures371 - Pages By type, bacterial consortia transplantation (BCT)/ fecal microbiota transplantation (FMT), live bacteria products, and others segment the human microbiome market. Live bacteria products accounted for the largest share of the human microbiome market in 2024. This category includes probiotics and synbiotics, which are widely used in consumer health supplements and emerging therapeutic applications. The dominance of live bacteria products is driven by strong consumer demand for digestive and immune health solutions, along with increasing clinical validation of specific bacterial strains. These products are often easier to formulate, regulate, and distribute compared to more complex microbiome therapies, allowing for faster commercialization. Additionally, ongoing advancements in encapsulation and delivery technologies have improved bacterial stability and survivability through the gastrointestinal tract, enhancing their effectiveness. The growing focus on personalized nutrition and preventive health has further expanded the adoption of live bacteria products across various age groups and health segments. Fecal microbiota transplantation/biological combination therapies (FMT/BCT) accounted for the second-largest share, supported by approved drugs such as VOWST and Rebyota for recurrent Clostridioides difficile infection. By end users, the human microbiome market is segmented by end users, hospitals & clinics, long-term care facilities, and other end users. Hospitals and clinics accounted for the largest share of the human microbiome market in 2024. This is largely due to their critical role in administering, monitoring, and regulating microbiome-based therapeutics, particularly those targeting infectious and gastrointestinal conditions. Approved products such as VOWST and Rebyota, used to prevent recurrent Clostridioides difficile infection, are typically prescribed and delivered in clinical settings under medical supervision. These facilities provide the necessary infrastructure for managing live microbial therapies, which may require cold-chain storage, specialized handling, and follow-up care. Hospitals and clinics are also key sites for clinical research, including patient enrollment for microbiome-based drug trials and real-world evidence studies. Their involvement enables close monitoring of patient outcomes, adverse events, and long-term therapeutic effects, all of which are essential for the advancement of microbiome science and regulatory approval processes. Moreover, the rising prevalence of chronic conditions linked to microbiome imbalance, such as inflammatory bowel disease and metabolic disorders, has led to increased hospital-based consultations and treatment protocols involving microbiome interventions. The presence of trained healthcare professionals, diagnostic tools, and institutional trust further supports the strong uptake of microbiome products within hospital and clinical environments. By geography, in 2024, North America accounted for the largest share of the human microbiome market. This leading position is supported by a well-established biotechnology ecosystem, strong research and development infrastructure, and the presence of major market players such as Seres Therapeutics, Seed Health, and IFF. The region has seen significant regulatory progress, with the US FDA approving the first microbiome-based drugs, including Rebyota and VOWST, for the prevention of recurrent Clostridioides difficile infection. These approvals have encouraged further investment in microbiome therapeutics and supplements. North America also has high adoption rates for probiotics, prebiotics, and synbiotics, driven by increasing consumer awareness of gut health and preventive wellness. The region supports a growing number of clinical trials and academic collaborations focused on the role of microbiomes in conditions such as gastrointestinal diseases, metabolic disorders, and cancer. Additionally, favorable healthcare spending, innovation funding, and regulatory clarity continue attracting startups and established firms. These combined factors reinforce the dominant position of North America in the global human microbiome market. Request Sample Pages : Some of the leading players in the market include Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc. (US), BioGaia (Sweden), and ExeGi Pharma (US), among others. Seres Therapeutics (US): Seres Therapeutics is one of the emerging players in the human microbiome market. The company's microbiome therapeutics platform significantly reduces the time typically required to advance therapeutics to the clinic and, ultimately, to the market. The company focuses on R&D to launch advanced products in the market. Its R&D expenses were USD 64.6 million for the year ending December 31, 2024. It specializes in creating oral live biotherapeutic products with defined bacterial consortia intended to modulate the human microbiome. Its lead product, VOWST (formerly SER-109), received FDA approval in April 2023 to prevent recurrent Clostridioides difficile infection. VOWST is the first FDA-approved orally administered microbiome therapeutic. In 2023, Seres Therapeutics implemented organizational changes, including workforce reductions and a narrowed R&D focus. In June 2024, the company entered into an agreement with Nestlé Health Science to transfer full commercialization rights for VOWST. The company continues to pursue clinical development of its remaining programs and maintains collaborations with academic and industry partners. FERRING B.V. (SWITZERLAND) Ferring Pharmaceuticals is a biopharmaceutical company involved in the development of microbiome-based therapeutics. The company operates in multiple therapeutic areas, including reproductive medicine, maternal health, gastroenterology, and urology. Ferring engages in internal research and external partnerships in the microbiome space. It acquired Rebiotix, a company developing live biotherapeutic products targeting the human microbiome. The company developed Rebyota, a fecal microbiota-based therapeutic indicated for preventing recurrent Clostridioides difficile infection. The product received FDA approval in November 2022 and is administered via enema. It has also collaborated with organizations such as Karolinska Institutet, Intralytix, MyBiotics, and PharmaBiome to explore live microbial consortia, bacteriophage-based therapies, and microbiome diagnostics. The company maintains manufacturing and R&D operations in various regions and continues to advance its microbiome programs across therapeutic categories through preclinical and clinical development stages. International Flavors & Fragrances Inc. (US) International Flavors & Fragrances (IFF) operates in the fields of flavor, fragrance, nutrition, and biosciences, with a growing focus on microbiome-based ingredients. The company has developed capabilities in precision fermentation and microbial strain engineering, enabling the industrial-scale production of next-generation probiotics, including strict anaerobes like Akkermansia. These technologies support ingredient development for applications in human and pet health, food, and supplements. IFF's HOWARU brand includes clinically studied probiotic strains such as HN001, HN019, NCFM, Bi-07, and Bl-04. These strains are formulated for specific health outcomes, including immune support, digestive health, stress response, early life development, and healthy aging. HN001 has regulatory recognition in markets like Brazil for reducing eczema risk in infants and pregnant women. IFF offers products such as HOWARU Protect and HOWARU Restore, each targeting different stages of life or health needs. The HOWARU brand includes clinically studied probiotic strains such as HN001, HN019, NCFM, Bi-07, and Bl-04. These strains are formulated for specific health outcomes, including immune support, digestive health, stress response, early life development, and healthy aging. HN001 has regulatory recognition in markets such as Brazil for reducing eczema risk in infants and pregnant women. IFF offers products like HOWARU Protect and HOWARU Restore, each targeting different stages of life or health needs. The microbiome innovation of IFF is supported by ongoing collaborations and a broader portfolio in synthetic biology, enabling the development of functional ingredients across consumer and health product categories. For more information, Inquire Now! Related Reports: Clinical Microbiology Market High Throughput Screening Market Microbiome Sequencing Services Market Rapid Microbiology Testing Market Laboratory Proficiency Testing Market Get access to the latest updates on Human Microbiome Companies and Human Microbiome Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets 登入存取你的投資組合
Yahoo
a day ago
- Yahoo
Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock
Miami, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ('ETST' or the 'Company'), a strategic holding company focused on acquiring and scaling high-potential businesses, today announced that its Board of Directors has approved a reduction of the Company's authorized shares of common stock from 350 million to 300 million. This strategic reduction in authorized shares of common stock is a direct reflection of the Board's confidence in the Company's current trajectory and its commitment to protecting long-term shareholder value. "This move by the Board of Directors aligns with our current goal of reducing the share count." said Giorgio R. Saumat, CEO of ETST. "It sends a clear signal to the investment community: we are confident in our financial health, strategic plan, and we are committed to preventing unnecessary shareholder dilution.' With the Company's outstanding share count at approximately 294.3 million, the Board determined that the previous authorization level of 350 million shares was no longer necessary given the Company's direction and financial planning. About Earth Science Tech, Inc. Earth Science Tech, Inc. operates as a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses. The Company's current operations include compounding pharmaceuticals, telemedicine and real estate development through its wholly owned subsidiaries: LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC ('Mister Meds'), and Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC., and an 80% interest in MagneChef. To learn more, please visit: LLC. based in Miami, Florida, is a fully licensed compounding pharmacy authorized to fulfill prescriptions in the following states and territories: Arizona, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Minnesota, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Rhode Island, Utah, Wisconsin and Puerto Rico. RxCompound is actively pursuing licensure in the remaining U.S. states. To learn more please visit: MisterMeds, LLC. Mister Meds, acquired on October 1, 2024, is in Abilene, Texas. The pharmacy received full compounding licensure in March 2025. It operates out of a 5,000 sq. ft. facility owned by Avenvi and includes advanced sterile compounding capabilities with both positive and negative pressure environments, as well as hazardous drug handling. Mister Meds is currently applying for licensure in states not yet serviced by RxCompound. To learn more please visit: Peaks Curative, LLC. Peaks is a telemedicine referral platform offering asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound and Mister Meds. The platform operates in states where either pharmacy is licensed. Through the development of its own healthcare provider network, and ongoing licensure expansion for both pharmacies, Peaks aims to offer services nationwide. In addition, the company has recently expanded into the veterinary market through the acquisition of To learn more please visit: Las Villas Health Care, Inc. Las Villas is a brick-and-mortar healthcare facility dedicated to the Spanish speaking community. Our expert-led services include advanced sexual health treatments, and customized solutions to enhance physical performance. We combine compassionate, personalized care with clear, trustworthy education—empowering you to take control of your health with confidence. To learn more please visit: LLC. Doconsultation was born with a passion to modernize the availability and delivery of home therapies. DOConsultations providers tailor a medication plan around your health and wellness goals and follow up with our patients to ensure results, while our partner pharmacies conveniently ship directly to your door. To learn more please visit: Avenvi, LLC. Avenvi is a diversified real estate company engaged in development, asset management, and financing. With a growing portfolio of real estate holdings, Avenvi provides turnkey solutions from development to end-user financing. It also manages investment activities for ETST and oversees the Company's ongoing $5 million share repurchase program. To learn more please visit: MagneChef MagneChef is a direct-to-consumer retail brand. Utilizing its patents and intellectual properties, the company aims to develop new products that can be marketed and sold online. Currently, the company has developed products for cooking. MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property. In addition, the company has recently expanded into the premium American-made BBQ tool brand market through the acquisition of BBQraft. To learn more please visit: About Earth Science Foundation, Inc. Earth Science Foundation Inc. a 501(c)(3) nonprofit organization incorporated on February 11, 2019, is the charitable arm of ETST. ESF accepts grants and donations to assist individuals who need financial support for prescription costs at both RxCompound and Mister Meds. SAFE HARBOR ACT: Forward-Looking Statements. Except for historical information, the matters discussed herein may be considered 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including, without limitation, future-oriented statements related to cash flow, gross margins, revenues, and expenses. These statements are based on and reflect our current expectations, estimates, assumptions and/or projections, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts. They may include forward-looking words such as 'expect,' 'expectation,' 'believe,' 'anticipate,' 'may,' 'could,' 'intend,' 'belief,' 'plan,' 'estimate,' 'target,' 'predict,' 'likely,' 'seek,' 'project,' 'model,' 'ongoing,' 'will,' 'should,' 'forecast,' 'outlook' or similar terminology. Forward-looking statements are subject to a number of risks and uncertainties that may cause the Company's actual results to differ materially from our intent, belief or current expectations, including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. Company Contact:Giorgio R. SaumatCEO and Chairman of the Board(305) 724-5684IR@